Navigation Links
NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders
Date:6/13/2013

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ --

NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation  at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia.

ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that would maintain constant levodopa plasma concentrations.

Details on the Presentations are as follows:

Title: Constant Therapeutic Levodopa Plasma Concentrations Maintained by Continuous Subcutaneous Administration of ND−0612, a Novel Formulation of Levodopa/Carbidopa
Abstract #: 452
Presenter: Peter LeWitt
Poster session: Parkinson's Disease: Clinical Trials
Date and time: Tuesday, June 18th, 12:30pm
Location: Bayside, level, 1 gallery B

Title: ND0612, A Novel Formulation of Levodopa/Carbidopa for Continuous, Subcutaneous Administration, Achieves Steady-State Levodopa Plasma Concentrations in Parkinson's Disease Patients
Abstract #: LBA26
Presenter: Nir Giladi
Poster session: Late Breaking Abstracts
Date and time: Wednesday, June 19th, 12:00pm
Location: Exhibit hall #5

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapies for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well-established oral drugs that achieve better efficacy. The company's lead products are ND0612, a novel sub-cutaneous drug formulation for the treatment of Parkinson's disease, and ND0801, a combination drug for the treatment of cognitive disorders in diseases such as ADD/ADHD, schizophrenia and Alzheimer's disease. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact:
Oded S. Lieberman, PhD MBA, Chairman & CEO
oded@neuroderm.com
Tel.: +972-8-946 2729; Cell: +1-617-517-6077


'/>"/>
SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
2. NeuroDerm to Present at the Jefferies 2013 Global Healthcare Conference in New York City
3. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
4. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
5. Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
8. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
9. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
10. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
11. Mindray Announces Appointment of Three Members to Its Executive Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides full-spectrum ... San Jose for hi-tech, pharmaceutical and biomedical devices ... its Fremont Innovation District, is excited to strategically partner with ... the hundreds of biotech, pharma and biomed companies throughout the ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... -- Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe and ... painful intercourse and other painful pelvic pain conditions such as pelvic floor ... ... ... -based start-up company, VuVatech LLC, fills a void in the women,s ...
Breaking Medicine Technology:
(Date:7/20/2017)... ROUGE, La. (PRWEB) , ... July 20, 2017 , ... ... to the staff. Dr. Dunbar received his BS in Biology from LSU, graduating summa ... the Medical School Class President. After his residency in St. Louis, Dr. Dunbar moved ...
(Date:7/20/2017)... ... , ... A budget proposal to switch to an alternate consumer price index, ... is a bad deal for older and disabled Americans, says The Senior Citizens ... more slowly than the conventional one that is currently used to determine the annual ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), ... based Health IT business unit of Constellation Inc., a move that will help the ... of operations in St. Louis, the acquisition is expected to help MTS ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... “Fidget”: a ... Sisk, a retired public high school music and drama teacher who was a summa ... educational career, including a “Teacher of the Year” award. After her retirement from public ...
(Date:7/18/2017)... , ... July 18, 2017 , ... The results of an international clinical trial, led ... therapy for a severe type of muscular dystrophy holds promise for a subgroup of patients. ... Craig McDonald and colleagues at 53 study sites in 18 countries describe the clinical ...
Breaking Medicine News(10 mins):